Effectiveness of oral contraceptives in the treatment of acne

Contraception

Volumn 58, Issue 3 SUPPL., 1998, Pages 29-33

  Redmond, Geoffrey P ^a,b  

^a Found for Devmtl Endocrinol Inc   (United States)

^b Center for Health Studies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS NORGESTIMATE;

ACNE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HORMONAL REGULATION; HUMAN; ORAL CONTRACEPTION;

EID: 0031769283     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0010-7824(98)00080-8     Document Type: Conference Paper

References (31)

1. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995;85:793-801.
2. Panser LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991;43:91-9.
3. Franks AL, Beral V, Cates W Jr, Hogue CJR. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol 1990;163:1120-3.
4. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46:327-34.
5. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990;42:497-506.
6. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971;110:713-20.
7. Ortho Pharmaceutical Corp. Ortho Tri-Cyclen® Prescribing Information. Raritan, NJ: Ortho Pharmaceutical Corp, February 1997.
8. Bergfield WF, Odom RB. Introduction. J Am Acad Dermatol 1995;32(suppl):S1.
9. Koo JY, Smith LL. Psychological aspects of acne. Pediatr Dermatol 1991;8:185-8.
10. Stern RS. Acne therapy. Arch Dermatol 1996;132:776-80.
11. Hensyl WR, ed. Stedman's Medical Dictionary, 25th ed. Baltimore, MD: Williams & Wilkins, 1990:16.
12. Wu SF, Kinder BN, Trunnell TN, Fulton JE. Role of anxiety and anger in acne patients: a relationship with the severity of the disorder. J Am Acad Dermatol 1988;18:325-33.
13. van der Meeren HLM, van der Schaar WW, van den Hurk CMAM. The psychological impact of severe acne. Cutis 1985;36:84-6.
14. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985;20:425-9.
15. Shuster S, Fisher GH, Harris E, Binnell D. The effect of skin disease on self image. Br J Dermatol 1978;99(suppl 16):18-9.
16. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987;17:25-32.
17. Lim C-CL, Tan T-C. Personality, disability and acne in college students. Clin Exp Dermatol 1991;16:371-3.
18. Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol 1989;14:194-8.
19. Marks R. Acne - social impact and health education. J R Soc Med 1985;78(suppl 10):21-4.
20. Cunliffe WJ. Acne and unemployment [letter]. Br J Dermatol 1986;115:386.
21. Gupta MA, Gupta AK, Schork NJ, Ellis CN, Voorhees JJ. Psychiatric aspects of the treatment of mild to moderate facial acne: some preliminary observations. Int J Dermatol 1990;29:719-21.
22. Arnold HL Jr, Odom RB, James WD, eds. Andrews' Diseases of the Skin: Clinical Dermatology, 8th ed. Philadelphia: W.B. Saunders, 1990.
23. Janaud A, Rouffy J, Upmalis D, Dain M-P. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand 1992;71(suppl 156):33-8.
24. Jung-Hoffman C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception 1988;38:593-603.
25. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
26. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.
27. Palatsi R, Hirvensalo E, Liukko P, et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Dermato-Venereol 1984;64:517-23.
28. Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Arzneim-Forsch/Drug Res 1988;38:932-4.
29. Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S. Multicenter trial of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception 1995;51: 225-9.
30. Hoppe G. Gestoden, an innovative progestogen. Contraception 1988;37:493-501.
31. Volpe A, Silferi M, Mauri A, et al. Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. Eur J Obstet Gynecol 1994;53:205-9.